Kalofonos Isabel, CCO, reported a transaction classified as return at Crinetics Pharmaceuticals, Inc. involving 55000.000000 shares for an estimated $2266550.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Commercial Officer
Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.
Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceut…
The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive…
The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effectiv…
The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Co…
0 other filings
0 recent txs